Literature DB >> 2723455

Inducible resistance to vancomycin in Enterococcus faecium D366.

R Williamson1, S Al-Obeid, J H Shlaes, F W Goldstein, D M Shlaes.   

Abstract

Strain D366, a clinical isolate of Enterococcus faecium, is resistant (minimum inhibitory concentration [MIC] 32 mg/L) to vancomycin. When exponential-phase cultures were exposed to half the MIC of vancomycin, a lag of 3-4 h occurred before growth resumed. Cells preexposed to 1/2 MICs of vancomycin did not show any lag. Pregrowth of D366 with vancomycin caused resistance to all glycopeptides tested. Pregrowth in vancomycin resulted in synthesis of a 3.95-kDa cytoplasmic-membrane-associated protein. This protein was correlated with resistance in mutants with high-level resistance, in the presence of NaCl, which inhibited the activity of vancomycin, and when several glycopeptides with varying activities were tested. Vancomycin-grown cells appeared abnormal and lysed at a much slower rate than did normal cells. We conclude that (1) vancomycin resistance in D366 is inducible; (2) resistance is correlated with the synthesis of 39.5-kDa cytoplasmic membrane protein; and (3) this protein play an additional role in the inhibition of normal lytic functions.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2723455     DOI: 10.1093/infdis/159.6.1095

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  57 in total

1.  The VANA glycopeptide resistance protein is related to D-alanyl-D-alanine ligase cell wall biosynthesis enzymes.

Authors:  S Dutka-Malen; C Molinas; M Arthur; P Courvalin
Journal:  Mol Gen Genet       Date:  1990-12

2.  Antimicrobial activity of MDL 62,873, a semisynthetic derivative of teicoplanin, in vitro and in experimental infections.

Authors:  M Berti; G Candiani; M Borgonovi; P Landini; F Ripamonti; R Scotti; L Cavenaghi; M Denaro; B P Goldstein
Journal:  Antimicrob Agents Chemother       Date:  1992-02       Impact factor: 5.191

Review 3.  Resistance of enterococci to glycopeptides.

Authors:  P Courvalin
Journal:  Antimicrob Agents Chemother       Date:  1990-12       Impact factor: 5.191

4.  In vitro detection of enterococcal vancomycin resistance.

Authors:  D F Sahm; L Olsen
Journal:  Antimicrob Agents Chemother       Date:  1990-09       Impact factor: 5.191

5.  Different modes of vancomycin and D-alanyl-D-alanine peptidase binding to cell wall peptide and a possible role for the vancomycin resistance protein.

Authors:  J R Knox; R F Pratt
Journal:  Antimicrob Agents Chemother       Date:  1990-07       Impact factor: 5.191

6.  Phenotypic and genotypic heterogeneity of glycopeptide resistance determinants in gram-positive bacteria.

Authors:  S Dutka-Malen; R Leclercq; V Coutant; J Duval; P Courvalin
Journal:  Antimicrob Agents Chemother       Date:  1990-10       Impact factor: 5.191

7.  Correlation of penicillin-induced lysis of Enterococcus faecium with saturation of essential penicillin-binding proteins and release of lipoteichoic acid.

Authors:  S al-Obeid; L Gutmann; R Williamson
Journal:  Antimicrob Agents Chemother       Date:  1990-10       Impact factor: 5.191

8.  Genetic linkage and cotransfer of a novel, vanB-containing transposon (Tn5382) and a low-affinity penicillin-binding protein 5 gene in a clinical vancomycin-resistant Enterococcus faecium isolate.

Authors:  L L Carias; S D Rudin; C J Donskey; L B Rice
Journal:  J Bacteriol       Date:  1998-09       Impact factor: 3.490

9.  Synergy and resistance to synergy between beta-lactam antibiotics and glycopeptides against glycopeptide-resistant strains of Enterococcus faecium.

Authors:  L Gutmann; S al-Obeid; D Billot-Klein; M L Guerrier; E Collatz
Journal:  Antimicrob Agents Chemother       Date:  1994-04       Impact factor: 5.191

10.  Effects of combinations of beta-lactams, daptomycin, gentamicin, and glycopeptides against glycopeptide-resistant enterococci.

Authors:  R Leclercq; E Bingen; Q H Su; N Lambert-Zechovski; P Courvalin; J Duval
Journal:  Antimicrob Agents Chemother       Date:  1991-01       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.